Apimeds Pharmaceuticals US, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
100 MATAWAN RD, MATAWAN, NJ, 07747
Mailing Address
100 MATAWAN RD, MATAWAN, NJ, 07747
Phone
848-201-5010
Fiscal Year End
1231
EIN
851099700
Financial Overview
FY2024
-$778K
Net Income
$422K
Total Assets
$1.37M
Total Liabilities
$32K
Stockholders' Equity
$410K
Cash & Equivalents
$-0.17
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13D/A Beneficial ownership amendment | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 20, 2026 | View on SEC |
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| 8-K/A Current report amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 11, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | January 26, 2026 | View on SEC |
| 8-K Current report of material events | January 2, 2026 | View on SEC |
| 8-K/A Current report amendment | December 10, 2025 | View on SEC |
Material Events
8-K
Legal Issue
March 26, 2026
High Impact
- Active Phase II clinical trial for lead drug APU-101 remains the company's primary value driver.
- Legal enforcement of a December 2025 voting agreement protects current board control.
8-K
Leadership Change
March 25, 2026
High Impact
- Total leadership overhaul with appointment of new CEO Youngjik Cho
- Strategic pivot from pharmaceutical R&D to high-growth consumer retail
8-K
Financial Distress
March 16, 2026
High Impact
- Regains compliance with NYSE American LLC's minimum bid price requirement, avoiding delisting.
- Maintains listing on a major exchange, crucial for liquidity, investor confidence, and future capital-raising efforts.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.